Cover Image
Market Research Report

Teva

Published by Datamonitor Healthcare Product code 603960
Published Content info 46 Pages
Delivery time: 1-2 business days
Price
Back to Top
Teva
Published: June 14, 2018 Content info: 46 Pages
Description

PharmaVitae explores Teva's prescription pharmaceutical performance and outlook over 2017-27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Snapshot

  • Overview - Teva will look to build on the launches of Austedo and fremanezumab to counter the company's heavy debt burden and erosion of Copaxone by generics.
  • Key themes - [1] Growth will come from Teva's specialty medicines business [2] Teva is financially restricted by its large debt burden accrued through the acquisition of Actavis Generics [3] Copaxone sales will continue to fall as generics erode its market share.
  • Out to 2022 - Teva sales will shrink by $521m as Copaxone revenue diminishes.
  • Out to 2027 - Teva will begin to grow its revenue by adding $1.2bn due to fremanezumab and Austedo sales.
  • Pipeline - Teva is developing biosimilars of Rituxan and Herceptin.
  • Events - In May 2018, the FDA extended the approval date of fremanezumab to September 2018. Analysis structure
  • Explore and visualize revenue dynamics in Teva's portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.

Quarterly review

  • What were the major highlights from Teva's latest earnings call and quarterly performance?

Strategy analysis

  • How is Teva strategically poised out to 2027?
  • What are Teva's key strengths, weaknesses, opportunities, and threats?
  • What are Teva's key catalysts during the current year?

Portfolio analysis

  • Why will specific therapy areas experience the largest growth and decline?
  • What are the detailed competitive dynamics at play in Teva's important therapeutic markets?
  • How is Teva adapting strategically to internal and external headwinds in preceding quarters?

Facts and figures

  • What is Teva's forecasted sales performance out to 2027?
  • What is the revenue trajectory of Teva's current top 10 products out to 2027?
  • Which therapy areas will experience the largest growth and decline?
  • What are the portfolio weightings of Teva based on the lifecycle of its products?
Table of Contents
Product Code: DMKC0135934

TABLE OF CONTENTS

OVERVIEW

  • Snapshot
  • Analysis structure

Q1 2018 REVIEW

  • Teva's outlook buoyed by new launches

Q4 2017 REVIEW

  • Teva will focus on higher-margin products to lessen debt concerns

Q3 2017 REVIEW

  • What were the highlights of Teva's Q3 earnings call?
  • Teva's debt burden deepens as credit rating is cut
  • Teva's strategy to reduce debt
  • Specialty pharmaceuticals pipeline update
  • Fremanezumab and Austedo launches will offset declines in Copaxone

STRATEGY ANALYSIS

  • Company background
  • Acquisition of Actavis Generics
  • Teva's involvement in scandals has reduced investor confidence
  • Teva's generics business has been hit by increased US price erosion
  • Previous CEO stepped down amid major company changes
  • Teva's SWOT analysis
  • Teva's key catalysts

PORTFOLIO ANALYSIS

2018

2017

FACTS AND FIGURES

  • Teva's prescription pharma sales outlook
  • Teva's regional pharma sales outlook
  • Teva's therapy area dynamics
  • Teva's growth drivers and resistors
  • Teva's lifecycle analysis
  • Teva's M&A strategy and history

BIBLIOGRAPHY

LIST OF FIGURES

  • Figure 1: Teva's prescription pharmaceutical sales ($m) and growth rate (%), 2014-27
  • Figure 2: Teva's therapy area dynamics, 2017-27
  • Figure 3: Teva's launch/core/expiry portfolio configuration, 2017-27

LIST OF TABLES

  • Table 1: Teva key product sales, Q1 2017-Q1 2018
  • Table 2: Sales of Teva's key specialty medicine products, Q4 2017 and full-year 2017
  • Table 3: Teva's sales by therapy area ($m), 2017-27
  • Table 4: Teva's prescription pharmaceutical sales by region ($m), 2017-27
  • Table 5: Teva's sales by therapy area ($m), 2017-27
  • Table 6: Teva's central nervous system portfolio sales, by product ($m), 2017-27
  • Table 7: Teva's respiratory portfolio sales, by product ($m), 2017-27
  • Table 8: Teva's key products, 2017-27
  • Table 9: Teva's sales by launch, core, and expiry portfolio ($m), 2017-27
  • Table 10: Teva's key merger and acquisition deals, 2006-18
Back to Top